Table 1. Main characteristics of studies regarding HIPEC for recurrent ovarian cancer.

Characteristics	Safra T	Fagotti A	Baiocchi G	Muñoz-Casares FC	Le Brun JF	Spiliotis J	Amira G
Year	2014	2012	2016	2009	2014	2015	2019
Location	Israel	Italy	Brazil	Spain	France	Greece	Egypt
Duration	N.A.	4 years	13 years	7 years	14 years	8 years	7 years
Design	Case-control	Case-control	Case-control	Case-control	Case-control	RCT	Case-control
Sample size (HIPEC/Non-HIPEC)	111 (27/84)	67 (30/37)	79 (20/59)	26 (14/12)	42 (23/19)	120 (60/60)	35 (15/20)
Median age (years)	HIPEC: 54.3; Non-HIPEC: 54.3	HIPEC: 51.0; Non-HIPEC: 55.0	HIPEC: 51.6; Non-HIPEC: 58.4	HIPEC: 54.0; Non-HIPEC: 54.0	N.A.	HIPEC: 58.3; Non-HIPEC: 58.1	N.A.
Cycles (number)	N.A.	N.A.	N.A.	N.A.	6	5	4
Completeness of cytoreduction (CC)	N.A.	HIPEC: CC-0 =96.7%; CC-1 =3.3%. Non-HIPEC: CC-0 =100%	HIPEC: CC-0 =79.3%; CC-1 =13.8%; CC-2 =3.4%; CC-3 =3.4%. Non-HIPEC: CC-0 =77.1%; CC-1 =12.4%; CC-3 =12.5%	HIPEC: CC-0 =64%. Non-HIPEC: CC-0 =58%	HIPEC: CC-0 =65.4%; CC-1 =17.3%; CC-2 =17.3%. Non-HIPEC: CC-0 =42.1%; CC-1 =5.2%; CC-2 =42.1%; NA =5.2%	HIPEC: CC-0 =65%. Non-HIPEC: CC-0 =55%	CC-0 and CC-1 for all cases and controls
HIPEC technique	Closed	Closed	Closed	Open	N.A.	Open (n=40); closed (n=20)	N.A.

RCT, randomized controlled trial; Cycles, mean number of chemotherapy cycles before secondary surgery; N.A., not available.